Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/33043
Title: Appearance of del(11q) in two patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and combination chemotherapy.
Authors: Campbell L.J.;Catalano J.V.;Arkell K.;Rayeroux K.C.;Cole-Sinclair M.F.
Institution: (Campbell, Rayeroux, Arkell) Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, Melbourne, Vic., Australia (Catalano) Department of Haematology, Monash Medical Centre, Melbourne, Vic., Australia (Cole-Sinclair) Department of Haematology, Alfred Hospital, Melbourne, Vic., Australia (Campbell) Victorian Cancer Cytogenetics Service, St. Vincent's Hospital Melbourne, PO Box 2900, Fitzroy, Vic. 3065, Australia
Issue Date: 18-Oct-2012
Copyright year: 2002
Publisher: Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom)
Place of publication: United Kingdom
Publication information: British Journal of Haematology. 118 (1) (pp 243-245), 2002. Date of Publication: 2002.
Abstract: Two acute promyelocytic leukaemia patients, treated with all-trans retinoic acid and combination chemotherapy, acquired a deletion of 11q within 12 months of diagnosis. One patient died in relapse, with both t(15;17) and del(11q) cell lines co-existing. Patient 2 remains in remission with del(11q) in 70% metaphases, despite normal marrow morphology. No deletion of the MLL gene was identified in the latter patient. The early appearance of a del(11q) is unusual, particularly without morphological evidence of myelodysplasia. We hypothesize that the del(11q) was therapy-induced but the absence of other genetic lesions has resulted in no accompanying morphological changes.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1046/j.1365-2141.2002.03553.x
PubMed URL: 12100154 [http://www.ncbi.nlm.nih.gov/pubmed/?term=12100154]
ISSN: 0007-1048
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/33043
Type: Article
Subjects: *promyelocytic leukemia/dt [Drug Therapy]
amsacrine/cb [Drug Combination]
amsacrine/dt [Drug Therapy]
antineoplastic agent/do [Drug Dose]
antineoplastic agent/dt [Drug Therapy]
cytarabine/cb [Drug Combination]
cytarabine/do [Drug Dose]
cytarabine/dt [Drug Therapy]
idarubicin/cb [Drug Combination]
idarubicin/dt [Drug Therapy]
*retinoic acid/cb [Drug Combination]
*retinoic acid/do [Drug Dose]
*retinoic acid/dt [Drug Therapy]
gene deletion
antineoplastic agent/cb [Drug Combination]
adult
article
bone marrow
*cancer combination chemotherapy
cancer recurrence
cancer regression
case report
*chromosome deletion
clinical feature
controlled study
death
disease course
human
male
myelodysplasia
priority journal
death
disease course
gene deletion
human
male
myelodysplasia
priority journal
article
adult
*promyelocytic leukemia / *drug therapy
bone marrow
*cancer combination chemotherapy
cancer recurrence
cancer regression
case report
*chromosome deletion
clinical feature
controlled study
Type of Clinical Study or Trial: Case series or case report
Appears in Collections:Articles

Show full item record

Page view(s)

8
checked on Aug 31, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.